BRPI0615785B8 - composição inibidora da absorção de colesterol compreendendo bactérias do gênero bifidobacterium - Google Patents

composição inibidora da absorção de colesterol compreendendo bactérias do gênero bifidobacterium

Info

Publication number
BRPI0615785B8
BRPI0615785B8 BRPI0615785A BRPI0615785A BRPI0615785B8 BR PI0615785 B8 BRPI0615785 B8 BR PI0615785B8 BR PI0615785 A BRPI0615785 A BR PI0615785A BR PI0615785 A BRPI0615785 A BR PI0615785A BR PI0615785 B8 BRPI0615785 B8 BR PI0615785B8
Authority
BR
Brazil
Prior art keywords
cholesterol absorption
bifidobacterium
absorption inhibitor
bacteria
subsp
Prior art date
Application number
BRPI0615785A
Other languages
English (en)
Inventor
Ishikawa Fumiyasu
Hayakawa Hiroko
Iino Tohru
Original Assignee
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Kk filed Critical Yakult Honsha Kk
Publication of BRPI0615785A2 publication Critical patent/BRPI0615785A2/pt
Publication of BRPI0615785B1 publication Critical patent/BRPI0615785B1/pt
Publication of BRPI0615785B8 publication Critical patent/BRPI0615785B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

inibidor da absorção de colesterol. é relatado uma bactéria pertencente ao gênero bifidobacterium que apresenta uma excelente habilidade de sobreviver em trato digestivo, tem um efeito de inibir a absorção de colesterol no trato intestinal, é excelente na melhora do metabolismo de lipídio (por exemplo, um efeito de reduzir o nível de colesterol no sangue) e apresenta uma alta taxa de sobrevivência após armazenamento. também é relatado um inibidor de absorção de colesterol usando a bactéria. o inibidor de absorção de colesterol compreende, como um ingrediente ativo, pelo menos um microorganismo selecionado de bifidobacterium animalis subsp. animalis yit 10394, bifidobacterium animalis subsp. lactis jcm 1253, bifidobacterium animalis subsp. lactis jcm 7117 e bifidobacterium pseudolongum subsp. globosum.
BRPI0615785A 2005-09-08 2006-09-07 composição inibidora da absorção de colesterol compreendendo bactérias do gênero bifidobacterium BRPI0615785B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005-260401 2005-09-08
JP2005260401 2005-09-08
PCT/JP2006/317748 WO2007029773A1 (ja) 2005-09-08 2006-09-07 コレステロール吸収抑制剤

Publications (3)

Publication Number Publication Date
BRPI0615785A2 BRPI0615785A2 (pt) 2011-05-24
BRPI0615785B1 BRPI0615785B1 (pt) 2019-07-02
BRPI0615785B8 true BRPI0615785B8 (pt) 2021-05-25

Family

ID=37835888

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0615785A BRPI0615785B8 (pt) 2005-09-08 2006-09-07 composição inibidora da absorção de colesterol compreendendo bactérias do gênero bifidobacterium

Country Status (10)

Country Link
US (1) US7993903B2 (pt)
EP (1) EP1923065B1 (pt)
JP (1) JP5116473B2 (pt)
KR (1) KR101270962B1 (pt)
CN (1) CN101257910B (pt)
AU (1) AU2006288252B2 (pt)
BR (1) BRPI0615785B8 (pt)
DE (1) DE602006018627D1 (pt)
ES (1) ES2355064T3 (pt)
WO (1) WO2007029773A1 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655932B2 (en) 2002-03-13 2017-05-23 Kibow Biotech, Inc. Composition and method for preventing or treating gout or hyperuricemia
US11103542B2 (en) 2002-03-13 2021-08-31 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
ITTO20070555A1 (it) * 2007-07-26 2009-01-27 Bioman S R L Biomassa arricchita in zinco, procedimento per la sua preparazione e prodotti probiotici, cosmetici, dietetici e nutraceutici comprendenti tale biomassa
MX2008006546A (es) * 2008-05-21 2009-11-23 Sigma Alimentos Sa De Cv Bifidobacteria productora de ácido fólico, composición alimenticia y uso de la bifidobacteria.
US9943614B2 (en) 2008-06-17 2018-04-17 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
FR2938552B1 (fr) 2008-11-19 2010-12-03 Gervais Danone Sa Souche hypocholesterolemiante de lactobacillus delbrueckii
CN101503667B (zh) * 2009-03-05 2010-12-01 浙江大学 一种耐氧性双歧杆菌
KR101838588B1 (ko) * 2010-12-09 2018-03-16 (주)아모레퍼시픽 발효차 추출물을 포함하는 지질 수준 감소용 조성물
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
KR102220710B1 (ko) 2011-07-20 2021-03-02 브라이엄 영 유니버시티 소수성 세라게닌 화합물 및 이를 포함하는 기구
ITRM20110477A1 (it) 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
CN104379120A (zh) 2011-12-21 2015-02-25 布莱阿姆青年大学 口腔护理组合物
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
WO2013165574A2 (en) 2012-05-02 2013-11-07 Brigham Young University Ceragenin particulate materials and methods for making same
DK2898061T3 (da) * 2012-09-20 2020-02-10 Prothera Inc Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
BR112015008804A2 (pt) 2012-10-17 2017-07-04 Univ Brigham Young tratamento e prevenção de mastite
US9943529B2 (en) 2013-01-07 2018-04-17 Brigham Young University Methods for reducing cellular proliferation and treating certain diseases
WO2014151411A1 (en) 2013-03-15 2014-09-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
MY183171A (en) * 2013-04-17 2021-02-18 Suntory Holdings Ltd Composition containing bacterium belonging to genus lactobacillus
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
CN103222990A (zh) * 2013-04-25 2013-07-31 四川农业大学 干酪乳杆菌和银杏叶提取物在制备防治高脂血症药物中的应用
ITMI20130793A1 (it) 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
ES2526986B1 (es) * 2013-07-18 2015-11-02 Biopolis, S.L. Nueva cepa de Bifidobacterium animalis subsp. lactis CECT 8145 y su uso para el tratamiento y/o prevención de sobrepeso y obesidad y enfermedades asociadas
CN103461515B (zh) * 2013-09-23 2014-10-29 光明乳业股份有限公司 一种霉菌成熟干酪及其制备方法
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
WO2015083743A1 (ja) 2013-12-04 2015-06-11 株式会社ヤクルト本社 微生物の酸耐性調節方法
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
CN104531590B (zh) * 2015-01-14 2017-12-08 贵州大学 一株香猪源性降胆固醇、耐氧双歧杆菌bz11
CN104560829B (zh) * 2015-01-14 2017-11-14 贵州大学 一株香猪源性降胆固醇、耐氧双歧杆菌bz25
WO2016172553A1 (en) 2015-04-22 2016-10-27 Savage Paul B Methods for the synthesis of ceragenins
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
EP3328208B1 (en) * 2015-07-31 2019-11-20 Compagnie Gervais Danone Methods for the preparation of fermented products comprising bifidobacteria
CN106107322A (zh) * 2015-09-25 2016-11-16 烟台大学 一种海带花生露及其制备方法
KR101653678B1 (ko) * 2016-01-12 2016-09-02 주식회사 프롬바이오 포도씨 추출물, 발레리안 추출물 및 홍화씨 추출물을 함유하는 여성 갱년기 증상 예방 및 개선용 식품 조성물
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
ITUA20162013A1 (it) 2016-03-24 2017-09-24 Probiotical Spa Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica.
KR20220001516A (ko) * 2016-04-14 2022-01-05 듀폰 뉴트리션 바이오사이언시즈 에이피에스 식품, 에너지 및/또는 지방 섭취 감소를 위한 비피더스균
US11179426B2 (en) 2016-12-29 2021-11-23 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
KR20200023432A (ko) 2017-06-26 2020-03-04 키보우 바이오테크 인코포레이티드 신장질환을 가진 환자에서 신장 기능을 유지시키고 및 개선시키는 방법 및 표준 관리 치료 방법
US11857579B2 (en) * 2018-03-23 2024-01-02 Morinaga Milk Industry Co., Ltd. Composition for promoting the secretion of FGF21
CN108570429A (zh) * 2018-05-08 2018-09-25 西藏高原之宝牦牛乳业股份有限公司 一种动物双歧杆菌及其制备方法
US12186328B2 (en) 2019-05-23 2025-01-07 Brigham Young University Use of CSA compounds to stimulate stem cells and hair growth
WO2021038975A1 (ja) * 2019-08-28 2021-03-04 株式会社アネロファーマ・サイエンス ダイアボディ型ＢｓＡｂを発現・分泌するビフィドバクテリウム属細菌
CN110551774A (zh) * 2019-09-24 2019-12-10 华侨大学 一种从海葡萄中酶法制备活性β-1,3-木寡糖的方法
CN113943683B (zh) * 2020-11-12 2023-07-04 江南大学 一株缓解便秘并增加粪便总胆汁酸含量的长双歧杆菌长亚种及其应用
EP4001399A1 (en) * 2020-11-13 2022-05-25 "NEOPHARM BULGARIA" Ltd. Strain bifidobacterium animalis ssp. lactis dsm 33647 for modulating metabolism indicators
KR102629635B1 (ko) * 2021-05-13 2024-01-30 주식회사 비티진 신규한 비피도박테리움 롱검 균주 및 이의 용도
US12350301B2 (en) * 2021-06-30 2025-07-08 Gi Biome Inc. Composition comprising three Lactobacillus sp. strains, and use thereof
CN114574407B (zh) * 2022-05-06 2022-11-01 微康益生菌(苏州)股份有限公司 动物双歧杆菌乳亚种wkb99及其在制备改善代谢综合征制品方面的应用和产品
CN116904346A (zh) * 2023-06-06 2023-10-20 石河子大学 动物双歧杆菌乳亚种hn-3在沙枣果汁发酵中的应用
KR20250112186A (ko) * 2024-01-16 2025-07-23 한국생명공학연구원 신규한 비피도박테리움 속 균주, 및 이를 유효성분으로 포함하는 지방간 질환 예방, 개선 또는 치료용 조성물
CN119351272A (zh) * 2024-12-04 2025-01-24 南京师范大学 一种假长双歧杆菌及其应用
CN121182574B (zh) * 2025-11-24 2026-03-10 孝感市宏龙麻糖米酒有限公司 一种应用于紫薯米酿的高效发酵工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61109729A (ja) 1984-11-05 1986-05-28 Advance Res & Dev Co Ltd コレステロ−ル低下剤
JPS61271223A (ja) 1985-05-24 1986-12-01 Biofuerumin Seiyaku Kk 血中脂質改善剤
JPH0696537B2 (ja) * 1986-05-02 1994-11-30 雪印乳業株式会社 血清コレステロ−ル上昇抑制剤
JP3384907B2 (ja) 1995-03-28 2003-03-10 雪印乳業株式会社 新規ビフィズス菌及びその利用
AU784898B2 (en) * 2000-01-18 2006-07-20 Societe Des Produits Nestle S.A. Pet food composition for treating helicobacter species in pets
EP1421945A4 (en) * 2001-08-10 2005-06-22 Hokkaido Tech Licensing Office ABSORBENT / ADSORBENT OF BILARY ACID
JP2003238423A (ja) 2002-02-15 2003-08-27 Morinaga Milk Ind Co Ltd 血中コレステロール低下剤および血中コレステロール低下飲食品
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum

Also Published As

Publication number Publication date
BRPI0615785A2 (pt) 2011-05-24
CN101257910B (zh) 2012-05-23
DE602006018627D1 (en) 2011-01-13
EP1923065B1 (en) 2010-12-01
WO2007029773A1 (ja) 2007-03-15
EP1923065A4 (en) 2009-08-26
US20090170185A1 (en) 2009-07-02
KR101270962B1 (ko) 2013-06-11
JP5116473B2 (ja) 2013-01-09
ES2355064T3 (es) 2011-03-22
US7993903B2 (en) 2011-08-09
EP1923065A1 (en) 2008-05-21
KR20080048468A (ko) 2008-06-02
AU2006288252B2 (en) 2012-01-12
CN101257910A (zh) 2008-09-03
JPWO2007029773A1 (ja) 2009-03-19
BRPI0615785B1 (pt) 2019-07-02
AU2006288252A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
BRPI0615785B8 (pt) composição inibidora da absorção de colesterol compreendendo bactérias do gênero bifidobacterium
Baktash et al. Mechanistic insights in the success of fecal microbiota transplants for the treatment of Clostridium difficile infections
Chen et al. Biological fates of tea polyphenols and their interactions with microbiota in the gastrointestinal tract: Implications on health effects
Nowak et al. Anti-proliferative, pro-apoptotic and anti-oxidative activity of Lactobacillus and Bifidobacterium strains: A review of mechanisms and therapeutic perspectives
Lin Antibiotic growth promoters enhance animal production by targeting intestinal bile salt hydrolase and its producers
Westfall et al. A novel polyphenolic prebiotic and probiotic formulation have synergistic effects on the gut microbiota influencing Drosophila melanogaster physiology
Malo et al. Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota
Vuotto et al. Probiotics to counteract biofilm-associated infections: promising and conflicting data
Kawabata et al. Flavonols enhanced production of anti‐inflammatory substance (s) by Bifidobacterium adolescentis: Prebiotic actions of galangin, quercetin, and fisetin
Dostal et al. Iron depletion and repletion with ferrous sulfate or electrolytic iron modifies the composition and metabolic activity of the gut microbiota in rats3
Kumar et al. Anticarcinogenic effect of probiotic fermented milk and chlorophyllin on aflatoxin-B1-induced liver carcinogenesis in rats
Seo et al. Partially purified exopolysaccharide from Lactobacillus plantarum YML009 with total phenolic content, antioxidant and free radical scavenging efficacy
Rätsep et al. A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection
US20230241129A1 (en) Probiotic to Enhance an Individual's Skin Microbiome
Sharma et al. Diet supplemented with phytochemical epigallocatechin gallate and probiotic Lactobacillus fermentum confers second generation synbiotic effects by modulating cellular immune responses and antioxidant capacity in aging mice
US11998574B2 (en) Method and system for modulating an individual's skin microbiome
NO20051651L (no) Naeringspreparater inneholdende synbiotiske forbindelser
BR0008911A (pt) Bactérias patogênicas da cepa lactobacillus para a prevenção de diarréia
Kataoka et al. Inhibitory effects of fermented brown rice on induction of acute colitis by dextran sulfate sodium in rats
de Llano et al. Strain-specific inhibition of the adherence of uropathogenic bacteria to bladder cells by probiotic Lactobacillus spp.
MY162076A (en) Use of vitamin e tocotrienols for the inhibition of intracellularly obligate pathogen chlamydia
Ambalam et al. Prebiotic preferences of human lactobacilli strains in co‐culture with bifidobacteria and antimicrobial activity against Clostridium difficile
Wu et al. Lactobacillus rhamnosus LB1 alleviates enterotoxigenic Escherichia coli-induced adverse effects in piglets by improving host immune response and anti-oxidation stress and restoring intestinal integrity
Solis-Velazquez et al. Nosocomial pathogen biofilms on biomaterials: Different growth medium conditions and components of biofilms produced in vitro
BR0008920A (pt) Cepas de lactobacillus capazes de prevenirdiarréia causada por bactéria patogênica erotaviroses

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/09/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2686 DE 28-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.